Daily Newsletter

21 November 2023

Daily Newsletter

21 November 2023

Vejle Hospital develops workflow with RayStation capabilities

The system will create a preliminary treatment plan based on the existing diagnostic CT scan.

November 21 2023

The University Hospital of Southern Denmark in Vejle has developed a new workflow enabled by RaySearch Laboratories’ RayStation adaptive replanning capabilities.

With this latest development, the hospital became the first in the world to use RayStation for an online adaptive treatment with augmented cone-beam computed tomography (CBCT).

The improved workflow is intended for adapting the treatment plan of a patient during the first treatment session and saves time for the patient.

RayStation will create a preliminary treatment plan based on the existing diagnostic CT scan instead of getting an additional scan.

The CT algorithm and adaptive replanning capabilities of RayStation allow the creation of an adapted plan using CBCT during the treatment session.

The first patient was a 65-year-old man with metastatic prostate cancer and was treated on 10 October, demonstrating the time-saving benefits.

The system claims to have the potential to address various anatomical changes in addition to differences in patient positioning during image acquisition and treatment.

RaySearch founder and CEO Johan Löf said: “Online adaptive has been a key focus for RaySearch for many years and I am impressed by the work that is done at Vejle.

“RayStation has very advanced tools available for taking online adaptive into clinical routine and the work done by Vejle is showcasing what groundbreaking possibilities our users have to further advance cancer treatments.”

RaySearch Laboratories develops software solutions for cancer treatment.

The company’s products include the RayStation treatment planning system and the RayCare oncology information system.

Additional offerings are RayIntelligence, an oncology analytics system, and RayCommand, a treatment control system.

RayStation is said to be flexible and adaptive, and supports various treatment machines, contributing to improved cancer patient care globally.

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close